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Abstract. Next-generation sequencing techniques and genome-wide association study analyses have provided a huge amount
of data, thereby enabling the identification of DNA variations and mutations related to disease pathogenesis. New techniques
and software tools have been developed to improve the accuracy and reliability of this identification. Most of these tools
have been designed to discover and validate single nucleotide variants (SNVs). However, in addition to germ-line mutations,
human tissues bear genomic mosaicism, which implies that somatic events are present only in low percentages of cells within
a given tissue, thereby hindering the validation of these variations using standard genetic tools. Here we propose a new
method to validate some of these somatic mutations. We combine a recently developed software with a method that cuts
DNA by using restriction enzymes at the sites of the variation. The non-cleaved molecules, which bear the SNV, can then be
amplified and sequenced using Sanger’s technique. This procedure, which allows the detection of alternative alleles present
in as few as 10% of cells, could be of value for the identification and validation of low frequency somatic events in a variety
of tissues and diseases.
Keywords: Alzheimer’s disease, identification of nucleotide variations, Sanger sequencing, somatic mutations, Virmid
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INTRODUCTION
A small number of Alzheimer’s disease (AD) cases
are caused by an inherited mutation in one of three
genes (APP, PSEN1, and PSEN2) [1]. However, the
vast majority of patients have the sporadic form
of the disease, which is related to the presence of
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several genetic and non-genetic risk factors [2]. Since
somatic mutations in single human neurons have been
identified [3, 4], it has been proposed that somatic
gene variations present in brain cells facilitate the
development of the disease [5, 6]. These variations
can arise during development or aging, as in the case
of other disorders such as cancer, and they may rep-
resent mosaic genomic heterogeneity [7].
It is difficult to confirm the detection of somatic
gene variations by standard procedures like Sanger’s
method when the number of cells bearing the partic-
ular gene variation or mutation is very low compared
with the rest of the cells. Indeed, Sanger sequencing
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allows the detection of somatic gene variations with
an allelic frequency of 20% or higher [8] in a given
sample. In this regard, other techniques, such as Illu-
mina sequencing, have been tested [6]. However, this
method can introduce errors in reading sequencing
alignments that can interfere with the identification
of true somatic variations [9, 10]. In an attempt
to decrease these errors, several approaches have
emerged [5, 10, 11]. However, it continues to be
difficult to apply Sanger’s sequencing for validation
purposes when variations are present in only a few
cells or when comparing samples from two different
tissues from the same individual and only one bears
the somatic gene variation.
Here we first developed a new method involving
Illumina sequencing and validation that allows the
characterization of somatic variations present in a
few brain cells and absent in other tissues like blood,
of a single subject. It is difficult to accurately iden-
tify a somatic SNV in the exome of a specific cell in
an environment containing many cells lacking that
particular SNV. New methods have recently been
proposed [5, 10–14], and new software, like Virmid
[15], has been developed to favor the detection of
somatic mutations without impurity interferences and
to avoid errors caused by non-suitable read align-
ments. In this way, the main aim of this work is
the development of a new method for the analysis
of somatic variants.
In the present study, we describe a method to iden-
tify exomic brain-specific somatic SNVs by Illumina
sequencing. The method is based on the following:
a) use of Virmid software [15] for data processing; b)
removal of the DNA lacking the SNV of interest by
digestion with a specific restriction nuclease; and c)
amplification and validation of the DNA containing
the SNV by Sanger sequencing. This amplification is
achieved by treating the DNA samples with specific
restriction endonucleases that recognize only those
sequences in which the SNV of interest is absent.
These samples are then cleaved. Finally, the DNA
bearing the SNV is amplified and subjected to Sanger
sequencing.
A limitation of this procedure is that the restric-
tion nuclease used to eliminate bulk DNA may not
always be available; however, when we performed
the nuclease step, there was good correlation between
the bioinformatics processing and the data obtained
by Sanger sequencing after nuclease treatment. This
finding indicates that this method is suitable to iden-
tify brain SNVs that occur in neurodegenerative
disorders like AD, and, in general terms, to identify
the SNVs present at low proportions in a particular
tissue.
MATERIALS AND METHODS
Samples from donors were obtained from the
Spanish Brain Bank (Banco de Tejidos CIEN [BT-
CIEN], http://bt.fundacioncien.es/) and from the
Biobancodel SistemaSanitarioPu´blico deAndalucı´a
(http://www.juntadeandalucia.es/salud/biobanco/).
When alive, donors gave their written informed
consent. The tissues were obtained using protocols
approved by the ethical committee of the two afore-
mentioned organizations. Our work was previously
approved by the ethical committee of our center
(Comite´ de ´Etica de la Investigacio´n conjunto CNB-
CBMSO, http://www.cnb.csic.es/ cei/). The methods
were carried out in accordance with the approved
guidelines. DNA was extracted using Qiagen kits
and following the manufacturer’s instructions.
The list of donors is indicated in Supplementary
Table 1.
Tissue sample preparation
Hippocampal tissues from donors were obtained as
follows: postmortem tissues were obtained through a
Table 1
SNVs from AD patients validated by the present method
Sample chr Pos(hg19) Gene Condon change Aa change Enzyme Cut-site 5 reads
AD1 4 151835421 LRBA Gca/Aca A363T Pst1 5’-CTGCA/G-3’ 4/67 (6%)
3’-G/ACGTC-5’
AD2 2 189853334 COL3A1 Gga/Tga G201* ECO0191 5’-RG/GNCCY-3’ 4/42 (9%)
3’-YCCNG/GR-5’
This table shows some of the additional somatic variations that we discovered in some hippocampus samples, but not in blood, using Virmid
software. All of the mutations in this table are in genes that have hippocampus-specific SNVs, as indicated previously [6] and a restriction
site for a restriction endonuclease, in such way that the presence of the mutation modifies that site. The table indicates the position of the
mutation (according to hg19 assembly of the genome), the gene in which it is found, ID in dbSNP (none of them were previously identified
in blood DNA samples), the amino-acid change caused, the enzyme that recognizes this site, and the percentage of reads with the mutation
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rapid pathological autopsy shortly after death. The
postmortem interval was 3 h. Immediately after the
autopsy, the fresh tissues were flash-frozen in isopen-
tane at –50◦C. Thereafter, each frozen tissue sample
was placed in a –80◦C freezer for long-term preserva-
tion. Frozen tissue samples from various brain regions
were obtained from the corresponding slices after 2-h
of temperature soothing. Each sample was obtained
with the aid of sterile disposable material and placed
into sterile cryo-tubes. Thereafter, the samples were
kept at –80◦C. Blood samples were obtained simul-
taneously with routine blood extraction.
DNA isolation
All genomic DNA samples were isolated from
blood or from the hippocampus, using Qiagen kits
(DNeasy Blood and Tissue, ref: 69504) and following
the manufacturer’s instructions.
Sample processing for exome sequencing
3.10–6 g of genomic DNA was fragmented to
an average size of 200 bp using a Covaris LE220
instrument. Short insert libraries were obtained using
the Illumina TruSeq DNA Sample Preparation Kit.
Exonic sequences were enriched using Nimble-
Gen Sequence Capture Human Exome 2.1M Array.
Paired-end sequences of 91 nucleotides from each
end were generated to an average of 50x coverage
using an Illumina HiSeq 2000 instrument. Sequences
were generated in fastaq format.
Oligonucleotides used for DNA ampliﬁcation
(PCR)
The oligonucleotides listed in Table 2 were used
for sequence amplification purposes. A concentra-
tion from 900 fM to 900 pM was used (see Fig. 6).
DNA for PCR was purified with Wizard® Plus SV
Minipreps DNA Purification System (Ref A1330),
following the manufacturer’s guidelines.
Ampliﬁcation of fragments bearing SNVs
For the experiment shown in Fig. 6, a modified
version of TruePrime™ technology from Sygnis™
was used as an alternative to amplify and specifically
enrich the samples containing the SNV of interest.
TruePrime™ is a multiple displacement amplifica-
tion (MDA) technology based on the combination of
29 DNA polymerase [16, 17] and TthPrimPol, a
DNA primase that synthesizes DNA primers for 29
DNA polymerase during the reaction, thus allow-
ing the amplification of very low concentrations of
DNA (Picher et al., submitted). The undigested DNA
fragments (100 pg) containing the SNV were dena-
tured (10 min at 95◦C) and sealed (60 min at 60◦C) to
form circular single-stranded DNA molecules using
Epicentre® CircLigase™ II (100 units in a final reac-
tion volume of 20l). Next, these circular DNA
molecules were amplified by TruePrime™ rolling
circle amplification in the presence of the hexanu-
cleotide (oligomer) (5’-ACCAAT-3’) containing the
motif for nuclease EC01091 (5’-ACCAAG-3’). In
order to specifically enrich the amplification prod-
ucts with molecules bearing the SNV of interest, the
G in this nuclease was changed to T—the SNV found
in the AD patient. An oligonucleotide complemen-
tary to the reverse strand found in the AD patient
was also added (5’-GGGTCA-3’). Briefly, the circu-
larized DNA fragments (10 pg in 2.5l) were first
denatured by adding 2.5l of buffer D and incubat-
ing 3 min at room temperature. The samples were
then neutralized by adding 2.5l of buffer N. The
amplification mix containing 26.8l of H2O, 5l
of reaction buffer, 5l of dNTPs, 5l of Enzyme 1
(TthPrimPol), and 0.7l of Enzyme 2 (ø29DNApol)
was added to the DNA samples, resulting in a final
reaction volume of 50l. When indicated, 90 pM
Table 2
Oligonucleotides used for DNA amplification by PCR. f means forward and r reverse
Oligo Seq. (5’−→3’) TM (◦C) Amplified region Gene SNV place
Or9g4 f AACAAGGAGTCATGTGGTCAAT 56.5 Chr11 : 56510303- OR9G4 Chr11 : 56510623(A−→G),
56511287 rs513873, gTa/gCa (codon)
Or9g4 r CCGCCATGCAGCAATTTGTA
COL3A1 f TCAGCCATTCCAGCATGCATAA 56–63 Chr2 : 189852934- COL3A1 Chr2 : 189853334 (G−→T)
189853611 somatic mutation
COL3A1 r AGCTCTGGGAAGTGGACTATT
LRBA f GTTACCATTTGCACACATCTC 52.5 Chr4 : 151,835,001- LRBA Chr4 : 151835421(C−→T),
151,835,841 somatic mutation, Gca/Aca (codon)
LRBA-r CTCAGTGGCATAGGATGCAG
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of each oligo (5’-ACCAAG-3’ and 5’-GGGTCA-3’)
was added to the reaction. Reaction mixtures were
incubated for 3 h at 30◦C, and ø29DNApol was inac-
tivated for 10 min at 65◦C to avoid degradation of
the amplification products. The amount of amplified
DNA obtained was approximately 1g, as deter-
mined by the Quant-iT™ PicoGreen® dsDNA Assay
Kit (Invitrogen, Life Technologies, Carlsbad, CA,
USA). In some cases, the mixture was incubated (1 h)
in the presence of 29 DNA polymerase and the
absence of TimePrime™ polymerase, followed by a
2-h incubation in the presence of both polymerases.
Sanger sequencing
Sanger sequencing for purified PCR products was
performed using Applied Biosciences (ABI) 3720xl
sequencers at GATC Biotech (Cologne, Germany).
Bioinformatics analysis
We proceeded in two different ways depending
on whether our goal was to obtain well-defined
SNVs with a homozygous or heterozygous genotype,
wherein each is present 100% (if homozygous) or
50% (if heterozygous) of the cells, or whether the
SNV is present in somatic mutations, where in each
variation it is present at less than 50%.
Detection of SNVs
Samples were aligned to the human refer-
ence genome version hg19 [18] using the BWA
aligner software [19] with default parameters. For
each case, all the samples were pre-processed
using Picard software to remove duplicate reads
(http://picard.sourceforge.net/). Local realignment
was performed around indels to improve SNV call-
ing in these conflictive areas (IndelRealigner from
the Genome Analyzer Toolkit, GATK, version 2.1–8
[20]). Base quality scores were recalibrated using
BaseRecalibrator from GATK. The UnifiedGeno-
typer algorithm from GATK was then used with
default parameters (see [21, 22] for details) to call
SNVs, and a first file including raw calls was
obtained. We then separated the indels from the rest
of the calls and considered only SNVs for the analy-
sis. These variants were filtered with VariantFiltration
(from GATK) using the following parameters: cov-
erage: DP > 10, DP > 20, DP > 50 or DP > 100,
depending on the case of study; QD < 2.0; FS > 60.0,
MQ < 35.0; HaplotypeScore > 13.0; MQRankSum
< –12.5 and ReadPosRankSum < –8.0. We selected
only calls that passed these filters. Variants were
annotated using the dbSNP database version 138 [23],
the UCSC human RefGene [24], and the snpEFF
software (version 2 0 5) [25]. In order to manipulate
the files containing variations and to determine how
many of these variations were unique or common to
different tissues, we used the VCFtools software [26].
Detection of somatic mutations
To detect somatic mutations, we used hippocampus
and blood samples from the same individual in each
case and analyzed them together. We proceeded with
the recalibration of the bases with BaseRecalibrator
from GATK. After obtaining the recalibrated files,
we used the Virmid software [15]. This algorithm
is used for SNP profiling in paired control-disease
samples with default parameters (taking, in our case,
hippocampus as diseased tissue and blood as control).
The mutations were obtained in VCF format and were
also annotated using the snpEFF software (version
2 0 5) [25].
The symbols for the human genes, indicated in this
work, suggested by HGNC are:
- LRBA (LPS responsive beige-like anchor pro-
tein) HGNC ID: HGNC: 1742
- COL3A1 (Collagen type III alpha-1 chain)
HGNC ID: HGNC: 2201
- OR9G4 (Olfactory receptor family 9 subfamily
G member 9) HGNC ID: HGNC:15322
RESULTS
Validation of the analysis on a previously
described SNV present in a high proportion of
the tissue analyzed
As a first step, we used our method on a sample con-
taining a previously described specific SNV. Using
Genome Analysis Tool Kit (GATK)[20] software and
following the recommended workflows for variant
analysis proposed by the developers of this soft-
ware, we previously identified among our samples
[6] a SNV present in heterozygosis and in homozy-
gosis (dbSNP ID: rs513873 A−→G) in position
chr11 : 56510623 (according to GRCh37 assembly of
human genome) in OR9G4 (olfactory receptor 9G4
gene, Fig. 1A). Using Virmid software, we confirmed
the presence of the SNV (Fig. 1A) and then validated
this finding by Sanger sequencing (Fig. 1B).
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Fig. 1. Scheme showing the gene region where the SNV, determined by Illumina, is present. A) A single nucleotide variation in or9f4r gene,
(dbSNP ID [2] : rs513873 A−→G), in position chr11 : 56510623 (according to GRCh37 assembly of human genome) was detected. In order
to test the efficiency of the Illumina-Virmid method, we sequenced three samples, with and without the variation, as described previously,
in such way that A/A is homozygous for the reference allele and it does not have the SNV, G/G is homozygous for the described SNV, and
A/G is heterozygous, having both the reference allele and the SNV respectively in each chromosome 11. The figure shows the alignments of
the processed reads in the flanking regions of this SNV. As can be seen, each sequence shows a concrete number of reads with the reference
allele and/or with the alternative allele (corresponding to the described SNV), thereby confirming its genotype (A/A, A/G, or G/G). B) This
figure shows the chromatograms resulting from the Sanger sequencing analysis of the fragments containing (or not) the previously described
SNV. The results obtained by Illumina sequencing described in Fig. 1A and the genotypes of the samples are corroborated here. The arrows
indicate the exact site where the SNV is found in the sequence, pointing to a single peak for the homozygous samples (A/A and G/G) and a
double peak for the heterozygous ones (A/G).
982 A. Gomez-Ramos et al. / Validation of Somatic Single Nucleotide Changes
To amplify a fragment containing the SNV site, we
designed two flanking DNA primers (see methods) to
obtain a short DNA fragment (718 bp) that included
this SNV. The single exon of OR9G4 holds the
AGTACT sequence, which, after the SNV, becomes
AGTGCT. The first sequence (double stranded)
5’AGTACT3’; 3’TCATGA5’ was cleaved by restric-
tion enzyme Sca1, which cuts the 5’AGT/ACT3’ site
(Fig. 2A). After treatment of total DNA with the
restriction enzyme, we found that only those DNA
molecules lacking the SNV were digested. As a con-
trol, treatment with the enzyme of homozygous DNA
for the SNV and for a control sample lacking it con-
firmed the previous results (Fig. 2B). This finding
shows that a specific restriction nuclease can be used
to cleave specific DNA sequences with or without
the SNV.
Detection of low frequency brain-speciﬁc SNVs
We next tested whether the above procedure was
useful to detect SNVs present less than 50% of
the cells. As a proof of concept, we used the pre-
viously PCR-amplified DNA fragments of 718 bp
corresponding to samples A/A (without the SNV and
homozygous for the reference allele) and G/G (with
the described SNV in both alleles and containing the
target sequence for the restriction enzyme Sca1). We
mixed these two DNA samples, which contain a dif-
ferent nucleotide in their sequences, at ratios of 1 : 1,
3 : 1, 5 : 1, and 10 : 1 (Fig. 3A) and repeated the pro-
cedure described above. The reference DNA sample
(A), present in a higher number of cells, was a suitable
target for the restriction nuclease Sca1 (AGTACT),
but not the DNA sample with the SNV (AGTGCT).
To remove the reference DNA sequence, we digested
the DNA mixture with Sca1. Next, we amplified and
purified the undigested DNA and characterized the
presence of the SNV by Sanger sequencing (Fig. 3B).
Our results indicated that the method was effective to
detect variants present in a 1/10 proportion. The main
problem encountered was the low recovery yield of
purified DNA after electrophoresis.
Identiﬁcation of somatic brain mutations present
in AD patients
We next sought to validate SNVs present in only
a few cells of brain tissue. In a previous study
on AD brains, we demonstrated the presence of
somatic SNVs in this tissue. These were found to be
absent in paired blood DNA samples. These analyses
were done by Illumina sequencing [6]. Here, using
Virmid software, we validated two of these low fre-
quency SNVs (Table 1). We also demonstrate that
the presence of these SNVs prevented DNA diges-
tion by specific nuclease restriction enzymes, thereby
resulting in the removal of bulk DNA lacking the
SNVs. These features may allow the use of the
method shown in Supplementary Figure 1 for low
frequency SNVs, detected by Illumina, by using stan-
dard Sanger sequencing.
From the SNVs shown in Table 1, we chose the
exome of a patient with a SNV in the COL3A1 gene
in position chr2 : 189853334 G−→T (see Fig. 4A).
After the bioinformatics processing (Virmid), we
found that this SNV was present in brain (9% of
total reads) and absent in blood tissue. Direct Sanger
sequencing of brain (Fig. 4B) and blood (Fig. 4C)
samples showed the absence of this SNV in both
blood and brain DNA. Since the presence of such
a low frequency SNV prevents DNA digestion by
nuclease Eco0109I, we digested brain DNA with this
nuclease to remove bulk DNA.
Figure 5 shows the scheme, indicating that when
the whole DNA (containing many molecules lack-
ing the SNV and a few molecules containing it) was
digested with Eco01091, only those molecules of
undigested DNA were isolated. These were later puri-
fied by gel electrophoresis, amplified by PCR, and
sequenced by Sanger’s method. However, we found
that DNA recovery after gel electrophoresis was very
low, thus hindering proper amplification of the resid-
ual DNA and the obtention of unequivocal data.
Speciﬁc ampliﬁcation of fragments bearing the
SNV of interest
First, a rolling circle replication approach was
designed to amplify only the circularized fragments
containing the SNV of interest. This was achieved
by combining 29 DNA polymerase with a spe-
cific hexanucleotide containing the nuclease motif for
EC01091 (5’-ACCAAG-3’), in which G was changed
to T—the somatic SNV to be detected. However,
the amount of DNA produced was insufficient for
DNA sequencing using Sanger’s method. Thus, we
used an alternative approach (TruePrime™), based on
29 DNA polymerase and TthPrimPol (Picher et al.,
submitted), to specifically and exponentially amplify
this very low amount of DNA. The circularized
DNA fragments containing the SNV were amplified
by rolling circle replication using TruePrime™ (see
Methods) in the presence of specific hexanucleotides,
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Fig. 2. Scheme showing the procedure developed to validate SNVs using restriction enzymes. A) The single nucleotide variation A−→G
was detected in such way that its presence modifies the recognition site for the restriction enzyme Sca1, thereby preventing its DNA cut. We
designed two specific DNA primers to amplify a short region (718 bp) covering the site of this SNV in the genome. This fragment results
in two small fragments (460bp + 258bp) when it does not contain the SNV or in a simple non-cleaved fragment (718 bp) when the SNV
is present. B) This image shows the result of cutting the PCR-amplified fragments (see Fig. 1B) for the restriction enzyme ScaI. Samples
were loaded in a 1% agarose gel after treatment with Sca1. Observe that, as indicated in 1B, the presence of the SNV prevents the enzyme
from cutting the site. In A/A, the entire original 718 bp fragment has been digested, resulting in two fragments of 460 + 256 bp, G/G is
homozygous for the SNV, so the cut has not occurred. Finally, in A/G, which is heterozygous for the SNV, there is a mix of the two previous
results, with one half of its DNA digested and the other not.
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Fig. 3. Method to amplify a sample bearing a SNV that is present in a low proportion. A) Two samples containing a short 718 bp PCR-
amplified DNA fragment having G/G or A/A, an SNV whose presence is crucial for the recognition of the restriction enzyme Sca1 (see Fig.
1), were mixed in different ratios (1 : 1, 3 : 1, 5 : 1, and 10 : 1), in such way that the sample in a lower proportion was G/G, thus containing
the SNV, and subsequently it was not recognized by the restriction enzyme Sca1. All the mixed samples were treated with this enzyme and
loaded in an 1% agarose gel. It can be observed that the band at 718 bp matches proportionally in intensity the ratio of the sample of DNA
with the SNV. B) The undigested band at 718 bp was recovered from the gel and sequenced by Sanger’s method. Observe that this uncut
band contains the described SNV.
in order to enrich the amplification products with
molecules bearing the SNV of interest (Fig. 6A). We
recovered at least 1g of amplified DNA per sample.
When this amplified DNA was sequenced by
Sanger’s method (Fig. 6C), we detected the described
SNV, although it generally appeared together with
some DNA lacking the variant. This observation
could be attributed to the presence of a low pro-
portion of undigested DNA lacking the SNV or to
the presence of a low amount of DNA from other
contaminant cells that result in a background of
other nucleotide sequences. This background was
more evident when brain tissue was analyzed, as
we consistently achieved cleaner sequences from
blood cells. Our results show that, by using specific
DNA digestion, the above procedure allows the detec-
tion of low frequency SNVs (see also Figs. 1–3).
In more detail, two variables for the amplification,
namely oligonucleotide concentration and order for
using (incubation) the 29 DNA polymerase and
TruePrime™ polymerase, were taken into account. In
the first case, increasing concentrations, from 900 fM
to 900 pM of oligos, were used. In the second case,
all the components of the amplification mixture were
added at the same time (method A) whereas for
Method B, all the components of the amplification
mixture (including 29 DNA polymerase), except
TruePrime™ polymerase, were added for a first
incubation (1 h – 30◦C). Afterwards, TruePrime™
polymerase was added for a further incubation of the
whole mixture (2 h – 30◦C) (see Fig. 6A).
Figure 6B shows the results obtained for different
samples amplified with distinct oligo concentrations
and by using Method A or Method B. The (Sanger’s)
sequences obtained are shown in Fig. 6C.
In brain samples, SNVs present in less than 9–10%
of total reads may be (Fig. 6) at the detection limit
for validation by this method. Indeed, using the
Virmid software, we observed the presence of spe-
cific SNVs in the other gene shown in Table 1 (see
also Supplementary Figure 1). We tested the method
described in Fig. 7 with the SNV found in position
chr4 : 151835421 G−→A of LRB. This SNV was
present at a low frequency in brain (6% of total reads)
and was not detected by standard Sanger sequenc-
ing (Supplementary Figure 2). This SNV was absent




Fig. 4. Figure showing the alignments of the reads for the exomes of two different tissues (hippocampus and blood) from the same individual
(2H). A) The alignments were detected for a somatic mutation by Virmid software (see methods). This site is in chromosome 2 in position
189853334 in COL3A1 and results in the change G−→T in that position. As can be seen, this variation is found in only 9% of the reads of
the hippocampus, while it is absent in blood. Thus, brain and blood samples were sequenced by Sanger’s method. B) Brain (hippocampal)
DNA sample containing the SNV present in COL3A1 in a low proportion was sequenced, but the SNV was not detected. C) Blood DNA
samples from the same person as in (A), lacking the SNV present in COL3A1, were also sequenced. Curiously, cleaner sequences were
obtained from blood than from brain samples.
in blood. The SNV was absent in the sequence 5’-
CTGCAG-3’, which was present in most of the DNA
molecules and is the cleavage motif for restriction
nuclease Pst1 (Table 1). Thus, we digested those
molecules lacking the SNV with Pst1 and amplified
the undigested DNA by PCR. However, since a very
low amount of DNA was obtained in the PCR amplifi-
cation, we were unable to obtain clear readouts after
Sanger sequencing. In an attempt to achieve a bet-
ter amplification, we used TruePrime™. We attained
only a modest improvement of the data and found
that the sequence with the specific SNV was contam-
inated by other sequences (Supplementary Figure 3).
We thus conclude that the procedure described herein
is suitable to validate low frequency allele varia-
tions present in at least 10% of DNA molecules by
Sanger sequencing. Indeed, similar results to those
of Supplementary Figure 3 were obtained when two
other genes, wasf3 and hsdl2, were tested (data not
shown).
DISCUSSION
Here we report a novel method (Fig. 7) to vali-
date low frequency SNVs previously identified by
Illumina sequencing in various tissues of a single
donor. This method involves bioinformatics process-
ing based on previously described methods [15].
Moreover, after removing the DNA lacking the
somatic variations by means of digestion with spe-
cific restriction nucleases that can differentiate the
presence of a single nucleotide, the remaining SNVs
can be validated by Sanger’s method. Although suit-
able nucleases are not always available for every SNV
found, the good correlation between bioinformatics
data and the cases validated by Sanger’s method after
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Fig. 5. Scheme showing the procedure developed to validate the presence of the SNV in hippocampus samples. As in the previous figure,
the presence of the SNV modifies the cut site for the restriction enzyme Eco0109I, which recognizes the site AGGACCC present in the
sequence. The variation modifies this sequence to ATGACCC, which is not recognized by the enzyme. Consequently, the sequence cannot
be cut. This feature allowed us to recover the non-digested band from a gel and to amplify the sample by PCR to carry out posterior sequence
analysis using Sanger’s method.
nuclease treatment support the suitability and robust-
ness of the bioinformatics procedures used to identify
low-frequency variants.
As a first test for the use of restriction nucleases,
we addressed whether we could fractionate DNA
containing or lacking a given SNV in a donor with
this SNV in heterozygosis. The gene containing the
SNV, OR9G4, has been previously analyzed and the
SNV reported (1000 genomes Project, http://www.
ncbi.nlm.nih.gov/variation/tools/1000genomes/), the
allele frequencies for the Iberian population being
A = 0.7009 and G = 0.2991. To look for specific a
SNV present in less than 1/10 of the total reads,
TruePrime™ technology (Picher et al., submitted)
was used for rolling circle DNA amplification. In this
technique, we used a specific oligomer primer whose
motif contained the SNV.
Moreover, the presence of somatic mutations in
single human neurons has recently been reported
using single-cell sequencing [3, 4], being the main
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Fig. 6. Amplification of brain DNA containing the specific SNV by TruePrime™ and Sanger’s sequencing of the same amplified sample. A)
Scheme of circular DNA amplification by TruePrime™ using oligonucleotides containing the specific SNV. B) Effect of oligo concentration
and method used for DNA amplification on obtaining the sequence bearing the SNV. C) Sequences, obtained by Sanger’s, of samples 2
(negative), 4, 5, 6, 7, and 8.
cause for the appearance of SNVs, damage that
could take place during transcription (see also the
review [27]).
Also, it has been suggested that the presence
of somatic SNVs induces the development of neu-
rodevelopmental diseases [28]. In addition, new
point mutations may occur at CpG dinucleotides, at
cytosines that could be methylated [29]. Codons for
arginine or glycine residues begin with a CG dinu-
cleotide, which may explain why arginine or glycine
is changed to other residues in a large proportion
of non-synonymous somatic mutations [30]. Curi-
ously, in one of our cases, we observed a change of a
glycine residue (Table 1). Also, we found that none
of the SNVs in Table 1 (AD patients) were described
as single nucleotide polymorphisms in genome-wide
association studies central data. However, the SNV
(non-demented controls) shown in Fig. 1 was already
indicated in GWAS central data. The previous results
are compatible with those SNVs shown in Table 1
arising by somatic mutations.
In relation to the genes analyzed in this study,
Or9g4 belongs to the olfactory receptor protein
family and is a member of the G-protein-coupled
receptors. The function of this member has not
been analyzed. Col3A1 encodes type III procolla-
gen, and mutations cause type IV Ehlers-Danlos
syndrome [31]. LRBA participates in intracellular
vesicle trafficking and its expression is induced by
lipopolysaccharide (LPS). Alterations in this gene are
associated with a syndrome of immune deficiency and
autoimmunity [32].
In summary, here we describe a method to iden-
tify low frequency somatic SNVs in non-proliferating
cells like neurons. These variations can later be val-
idated by Sanger sequencing. This method includes:
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Fig. 7. Scheme showing the method developed in this work to detect somatic mutations that can be validated by Sanger’s sequencing. After
obtaining DNA samples from blood and hippocampus, their exomes were processed as indicated in materials and methods to obtain the
reads in fastaq format in each case. A first process was made to obtain the sequences in bam format, using some of the tools included in
GATK software [20]. These tools were: Indel realigned, Mark Duplicates and table recalibration (see methods) and the files were obtained in
recal.bam form. After this, we processed the recal.bam files coming from blood and hippocampus samples with Virmid software, comparing
hippocampal and blood samples in each case to obtain somatic mutations in hippocampus. The additional processes include looking for
somatic mutations that are present in restriction nuclease motifs for a specific endonuclease. The use of that enzyme to enrich the sample
having the SNV (due to the fact that its DNA can not be cut by the enzyme) and the recovery of this uncut sample from a gel and its
amplification by PCR (when the SNV is present in at least 10% of the cells) or by using True Prime™ when a lower percentage of cells (or
a very low amount of DNA) showing the SNV are present, may result in having a proper amount of DNA. Finally, sequencing by Sanger’s
method can be done.
a) the use of Virmid software; b) the removal of
the DNA molecules lacking the somatic SNV by
restriction nuclease digestion; and c) amplification of
the DNA molecules containing the SNV of interest
by means of TruePrime™ technology and oligonu-
cleotides containing the motif in which the SNV is
present. The limitations of the method are that there
is not always a restriction nuclease available to digest
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DNA lacking the SNV of interest and that the minimal
percentage of alternative reads that can be reliably
validated by Sanger sequencing is 10% when brain
tissue is used. Thus, the method proposed could be
of help for validating low frequency tissue-specific
mosaicism not only in the brain and in neurological
diseases but in any tissue of interest. Furthermore,
our data support the reliability of Virmid software
to identify low frequency SNVs in Next-generation
sequencing data.
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